Trial Profile
A prospective study evaluated tolerability and pharmacokinetics (PK) of two dosing regimens of LY-2944876 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 25 Apr 2016 New trial record
- 12 Mar 2016 Results (n=24) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.